Duncan Armstrong, Guy Leech take aim at $6.3bn supplements market
Australia’s $6.3bn supplements market is facing criticism from two former Australian sporting stars who believe too many older…
FDA Completes First-Cycle Review of Preservative-Free Ketamine ANDA with No Drug Related Major Deficiencies; Final Packaging Certification Requested for Approval
NRx Pharmaceuticals, Inc. FDA identified no major deficiencies related to the ketamine drug product, ingredients, proposed labeling, CMC,…
Hawke Electric Vehicles Expands Hire and Sales Operations to Full Nationwide Coverage Across the UK
Hawke Electric Vehicles has expanded its electric vehicle hire and sales operations to full nationwide coverage, with vehicle…
Results of Fundraise and TVR
Pulsar Helium THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR…
Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
Moleculin Biotech, Inc. Moleculin Biotech, Inc. INTERIM EFFICACY – N=45 INTENT TO TREAT (ITT) Both Annamycin dose arms…
Cycurion, Inc. Completes Transformative Acquisition of Secuvant, LLC and Flagship Panoptic Cybersecurity Platform
MCLEAN, Va., June 09, 2026 (GLOBE NEWSWIRE) — Cycurion, Inc. (NASDAQ: CYCU) (“Cycurion” or the “Company”), a leading…
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom
Rein Therapeutics 16 patients enrolled to date in trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) First patient…
Ocean Power Technologies Expands International Defense Engagements Across Europe
Ocean Power Technologies, Inc. MONROE TOWNSHIP, N.J., June 01, 2026 (GLOBE NEWSWIRE) — Ocean Power Technologies, Inc. (NYSE…
Tonix Pharmaceuticals Reports First Quarter 2026 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. In the first full quarter since launch, 2,145 healthcare providers prescribed TONMYA®, 3,588 patients…
Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression
In the Phase 3 study population (N=90) of patients with PPD, LPCN 1154 did not show a statistically…
PepGen Announces Topline Results from Lowest Dose (5 mg/kg) MAD Cohort in the Ongoing Phase 2 FREEDOM2 Study Demonstrating Favorable Safety, Splicing and vHOT Data
– PGN-EDODM1 was generally well-tolerated with all adverse events mild or moderate and no serious adverse events reported…
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Tonix Pharmaceuticals Holding Corp. TONMYA™ (cyclobenzaprine HCl sublingual tablets) launched November 17, 2025, for the treatment of fibromyalgia;…